Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976452 | 0.90 | EHMT2 (0.45) | BRD4RAPGEF4EHMT2 | |
| SCHEMBL1842397 | 0.89 | RAPGEF4 (0.46) | BRD4ATAD2RAPGEF4EHMT2 | |
| SCHEMBL14577966 | 0.86 | BRD4 (0.42) | BRD4ATAD2KCNH2HRH4HRH3 | |
| SCHEMBL21460303 | 0.80 | KCNH2 (0.43) | BRD4ATAD2KCNH2HRH4HRH3 | |
| SCHEMBL20135621 | 0.76 | BRD4 (0.50) | BRD4ATAD2KCNH2HRH4HRH3 | |
| SCHEMBL20134805 | 0.76 | BRD4 (0.50) | BRD4ATAD2KCNH2HRH4HRH3 | |
| SCHEMBL20134803 | 0.76 | BRD4 (0.50) | BRD4ATAD2KCNH2HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL29688363 | 0.74 | BRD4 (0.49) | BRD4ATAD2KCNH2HRH4HRH3 | |
| SCHEMBL2535679 | 0.73 | HRH4 (0.45) | BRD4ATAD2HRH4HRH3HRH2 | |
| SCHEMBL20353196 | 0.73 | TAS1R3 (0.51) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | BRD4 1957/4885ATAD2 693/4885RAPGEF4 3949/4885 |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | BRD4 1957/4885ATAD2 693/4885RAPGEF4 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.